2026年8月19日，国药控股股份有限公司（01099）发布海外监管公告称，其附属公司中国医疗器械有限公司已于当日在中国货币网及上海清算所网站刊发《2026年半年度报告》，相关文件仅供投资者参阅。公告强调，香港交易及结算所有限公司及香港联合交易所有限公司对公告内容的准确性或完整性不承担任何责任。
本次公告由国药控股股份有限公司董事长晋斌代表董事会发布。公司董事会成员构成如下：执行董事连万勇、杨秉华；非执行董事晋斌、陈启宇、祖敬、邢永刚、马跃、陈玉卿、文德镛、李莹；独立非执行董事李培育、吴德龙、俞卫锋、石晟昊、陈威如。
公告指出，中国医疗器械有限公司的半年度报告已在境内指定信息披露平台公开，港股投资者可通过相关网站查阅完整内容。公司未在本次公告中披露具体财务数据，后续如有进一步信息，将按照监管要求及时披露。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.